ObvioGo’s powerful and flexible technology has been designed to capture, integrate, and analyze more accurate multi-source data, empowering clinical science teams to generate stronger therapeutic evidence with ease.Book a Demo
Today’s DCT technology helps to reduce patient burden, but it hasn’t addressed the problems of inaccuracy and interoperability needed to deliver robust outcomes and endpoints.
ObvioGo has been designed and built to reduce friction for all stakeholders across all touch points. Powered by five interoperable modules, this next-generation DCT platform and mobile app incorporates best-in-class digital instruments, AI, and machine learning with intuitive interfaces and seamless integrations to deliver more robust and reliable clinical outcomes with less burden on patients, study teams, and sponsors.
Success Starts Here:
Optimize study build and accelerate amendment time
Configurable, adaptive design tools enable preview, testing, and iteration, allowing sponsors to optimize studies in real time and to pivot with peace of mind.
Outcomes Capture & Assessment
Capture more accurate data
Traditional eCOA methods are paired with AI-assisted digital instruments, wearables, and remote patient monitoring devices to improve data accuracy.
Frictionless patient interfaces
The intuitive ObvioGo mobile app reminds, nudges, and accompanies participants towards completion.
Increase compliance and retention
Built-for-purpose technology facilitates real-human interactions for increased engagement.
Make data oversight more efficient
Centralized tools and integration with existing clinical systems enable study teams to advance more quickly to analytical review.
The shift to remote and digital data collection opens the door to richer and stronger efficacy and safety signals. But, current DCT technology isn’t sufficiently user-friendly, causing friction for sites, patients, and CROs.
Designed with real people—sponsors, study teams, sites, and patients—in mind to remove friction, improve accuracy, and support the humans who make trials successful.
Outcomes Capture & Assessment
Say no to “one size fits all.” You need options that optimize and adapt.
Today’s DCT study designs are too often digital copies of poor traditional assessments. The power to deliver stronger endpoints is massively underleveraged in current DCT designs. ObvioHealth’s clinical science and tech teams work together to help sponsors optimize their endpoints. Our fully configurable study design tools have modular components that easily adapt to each project’s unique parameters across therapeutic areas and geographies.
Powerhouse tools to capture more accurate data from patients, clinicians, and caregivers.
Current DCT technologies make it easier to report remotely, but that doesn’t mean they are user-friendly. ObvioGo’s outcomes capture and assessment capabilities include AI-assisted technologies that facilitate the collection of more accurate data from all users: patients, clinicians, and caregivers.
Intuitive user interface and behavioral nudges keep participants on track from start to finish.
ObvioGo’s mobile app eliminates the need for provisioned devices. The user-friendly interface is based on extensive insight into the digital behaviors of trial participants, seamlessly incorporating study activities into participants' daily lives.
Meet your milestones with personalized patient support and team collaboration.
Tech may ease the clinical trial journey, but it’s humans who power it. ObvioGo’s study management tools facilitate the essential human interactions that are the heart of successful studies, with easy workflows and conversational interfaces to help study teams engage with participants and encourage them toward compliance and completion.
Deeper analyses for stronger therapeutic evidence.
ObvioGo’s cloud native platform securely stores all data, integrates with enterprise clinical research systems, and can be deployed globally, empowering clinical science teams to perform deeper analyses and generate stronger therapeutic evidence.
Built based on the execution of 50+ fully virtual and hybrid studies across 28 countries.
Designed by clinical and digital experts to improve ease and accuracy.
AI-enabled, evidence-generation engine empowers the delivery of stronger endpoints.